Clene Inc.

Contributing Author

Recent Articles by Clene Inc.

Nov-04	Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights CLNN +8.75% GlobeNewswire
Oct-19	Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS CLNN +6.13% GlobeNewswire
Sep-22	Clene to Present at Upcoming Investor Conferences CLNN GlobeNewswire
Sep-21	Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8 NDA CLNN GlobeNewswire
Sep-15	Clene Announces $4 Million Registered Direct Offering CLNN +22.56% GlobeNewswire
Sep-03	Clene to Present at Upcoming September Investor Conferences CLNN GlobeNewswire
Aug-17	Clene to Present at the Emerging Growth Conference CLNN GlobeNewswire
Aug-14	Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights CLNN GlobeNewswire
Aug-10	Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval CLNN GlobeNewswire
Jul-29	Clene to Present at The Canaccord 46th Annual Growth Conference CLNN -5.41% GlobeNewswire
May-14	Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights CLNN +8.46% GlobeNewswire
May-05	Clene Announces $7 Million Underwritten Offering of Common Stock CLNN -18.67% GlobeNewswire
May-05	Clene to Present at Upcoming May Conferences CLNN -18.67% GlobeNewswire
May-04	After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS CLNN +31.76% GlobeNewswire
Mar-12	Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights CLNN +6.09% GlobeNewswire
Feb-24	Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts CLNN +9.80% GlobeNewswire
Feb-19	Clene to Present at the Emerging Growth Conference CLNN GlobeNewswire
Jan-16	Clene to Present at the Emerging Growth Conference CLNN GlobeNewswire
Jan-12	Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting CLNN -19.00% GlobeNewswire
Jan-09	Clene Announces Registered Direct Offering of Over $28 Million CLNN +7.12% GlobeNewswire
Dec-09	Clene to Present at the Emerging Growth Conference CLNN +6.31% GlobeNewswire
Dec-03	Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 CLNN -22.03% GlobeNewswire
Dec-02	Clene to Provide CNM-Au8 ALS Program Update CLNN GlobeNewswire
Nov-20	Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference CLNN GlobeNewswire
Nov-13	Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights CLNN -22.42% GlobeNewswire
Oct-20	Clene to Present at the Emerging Growth Conference CLNN GlobeNewswire
Oct-15	Clene to Participate in a Panel Discussion at the Maxim Growth Summit CLNN GlobeNewswire
Sep-25	Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8 Improves Brain Energy Metabolism in Multiple Sclerosis Patients CLNN GlobeNewswire
Sep-04	Clene Presents Preclinical Data Supporting CNM-Au8 for the Treatment of Parkinson's Disease CLNN +6.44% GlobeNewswire
Sep-02	Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference CLNN +20.11% GlobeNewswire
Aug-14	Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights CLNN GlobeNewswire
Aug-13	Clene to Present at the Emerging Growth Conference CLNN GlobeNewswire
Aug-05	Clene to Present at the Canaccord 45th Annual Growth Conference CLNN GlobeNewswire
Jun-30	Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings CLNN GlobeNewswire
May-07	Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights CLNN -10.53% GlobeNewswire

Clene Inc.

Recent Articles by Clene Inc.

Upgrade your Finviz experience